T-cell populations specific for EBV antigens (SFCs/1 × 105 CTLs) in infusion product
Patient no. . | LMP1 . | LMP2 . | EBNA1 . | EBNA2/3 . | Lytic cycle . |
|---|---|---|---|---|---|
| 729 | YLQ: 0 | CLG: 0 | ND | DTP: 0 | TDL: 3.5 |
| YLL: 0 | GLG: 0 | LLD: 0 | YVL: 31 | ||
| FLY: 1988 | AVF: 0 | GLC: 1236 | |||
| LLW: 0 | IVT: 0 | ATI: 0 | |||
| LTA: 0 | NPT: 0 | ||||
| TVC: 0 | LPG: 0 | ||||
| LIV: 0 | DEP: 0 | ||||
| SSC: 27 | |||||
| 606 | YLQ: 0 | CLG: 45 | ND | DTP: 24 | TDL: 50 |
| YLL: 30 | GLG: 0 | LLD: 0 | YVL: 45 | ||
| FLY: 6 | GLC: 1824 | ||||
| LLW: 0 | |||||
| LTA: 0 | |||||
| TVC: 82 | |||||
| LIV: 750 | |||||
| IED: 830 | |||||
| 697 | YLQ: 0 | CLG: 33 | ND | DTP: 0 | TDL: 12 |
| YLL: 0 | GLG: 0 | LLD: 256 | YVL: 60 | ||
| FLY: 156 | VEI: 0 | GLC: 480 | |||
| LLW: 4 | EGG: 96 | ||||
| LTA: 0 | KEH: 0 | ||||
| TVC: 0 | EEN: 3 | ||||
| LIV: 0 | |||||
| 845 | ND | FTA: 0 | HPV: 0 | RPP: 125 | EPL: 0 |
| QPR: 0 | |||||
| RLR: 0 | |||||
| YPL: 0 | |||||
| AVL: 0 | |||||
| 894 | ND | RRR: 3 | HPV: 1588 | RRI: 160 | EPL: 1124 |
| RRL: 52 | YPL: 26 | ||||
| AVL: 72 | |||||
| 389 | YLQ: 0 | CLG: 26 | ND | DTP: 0 | TDL: 4 |
| YLL: 0 | GLG: 0 | LLD: 0 | YVL: 7 | ||
| FLY: 0 | VEI: 0 | GLC: 934 | |||
| LLW: 0 | EGG: 398 | ||||
| LTA: 0 | KEH: 0 | ||||
| TVC: 0 | EEN: 506 | ||||
| LIV: 0 | RLR: 0 | ||||
| 918 | ND | SSC: 8 | ND | AVF: 1214 | ATI: 0 |
| FTA: 0 | IVT: 1420 | ||||
| NPT: 0 | |||||
| LPG: 0 | |||||
| DEP: 0 | |||||
| 1042 | YLQ: 0 | CLG: 0 | ND | DTP: 0 | DYC: 0 |
| YLL: 0 | GLG: 0 | LLD: 0 | TDL: 0 | ||
| FLY: 0 | RYS: 0 | YVL: 0 | |||
| LLW: 0 | TYS: 0 | GLC: 0 | |||
| LTA: 0 | |||||
| TVC: 317 | |||||
| LIV: 0 | |||||
| PYL: 0 | |||||
| TYG: 0 | |||||
| 1046 | ND | FTA: 20 | ND | ND | ND |
Patient no. . | LMP1 . | LMP2 . | EBNA1 . | EBNA2/3 . | Lytic cycle . |
|---|---|---|---|---|---|
| 729 | YLQ: 0 | CLG: 0 | ND | DTP: 0 | TDL: 3.5 |
| YLL: 0 | GLG: 0 | LLD: 0 | YVL: 31 | ||
| FLY: 1988 | AVF: 0 | GLC: 1236 | |||
| LLW: 0 | IVT: 0 | ATI: 0 | |||
| LTA: 0 | NPT: 0 | ||||
| TVC: 0 | LPG: 0 | ||||
| LIV: 0 | DEP: 0 | ||||
| SSC: 27 | |||||
| 606 | YLQ: 0 | CLG: 45 | ND | DTP: 24 | TDL: 50 |
| YLL: 30 | GLG: 0 | LLD: 0 | YVL: 45 | ||
| FLY: 6 | GLC: 1824 | ||||
| LLW: 0 | |||||
| LTA: 0 | |||||
| TVC: 82 | |||||
| LIV: 750 | |||||
| IED: 830 | |||||
| 697 | YLQ: 0 | CLG: 33 | ND | DTP: 0 | TDL: 12 |
| YLL: 0 | GLG: 0 | LLD: 256 | YVL: 60 | ||
| FLY: 156 | VEI: 0 | GLC: 480 | |||
| LLW: 4 | EGG: 96 | ||||
| LTA: 0 | KEH: 0 | ||||
| TVC: 0 | EEN: 3 | ||||
| LIV: 0 | |||||
| 845 | ND | FTA: 0 | HPV: 0 | RPP: 125 | EPL: 0 |
| QPR: 0 | |||||
| RLR: 0 | |||||
| YPL: 0 | |||||
| AVL: 0 | |||||
| 894 | ND | RRR: 3 | HPV: 1588 | RRI: 160 | EPL: 1124 |
| RRL: 52 | YPL: 26 | ||||
| AVL: 72 | |||||
| 389 | YLQ: 0 | CLG: 26 | ND | DTP: 0 | TDL: 4 |
| YLL: 0 | GLG: 0 | LLD: 0 | YVL: 7 | ||
| FLY: 0 | VEI: 0 | GLC: 934 | |||
| LLW: 0 | EGG: 398 | ||||
| LTA: 0 | KEH: 0 | ||||
| TVC: 0 | EEN: 506 | ||||
| LIV: 0 | RLR: 0 | ||||
| 918 | ND | SSC: 8 | ND | AVF: 1214 | ATI: 0 |
| FTA: 0 | IVT: 1420 | ||||
| NPT: 0 | |||||
| LPG: 0 | |||||
| DEP: 0 | |||||
| 1042 | YLQ: 0 | CLG: 0 | ND | DTP: 0 | DYC: 0 |
| YLL: 0 | GLG: 0 | LLD: 0 | TDL: 0 | ||
| FLY: 0 | RYS: 0 | YVL: 0 | |||
| LLW: 0 | TYS: 0 | GLC: 0 | |||
| LTA: 0 | |||||
| TVC: 317 | |||||
| LIV: 0 | |||||
| PYL: 0 | |||||
| TYG: 0 | |||||
| 1046 | ND | FTA: 20 | ND | ND | ND |
CTL lines were screened for the presence of T-cell populations specific for the indicated antigens by IFN-γ ELISPOT. The panel of peptides used for stimulation was based on the HLA type of the patient (Table 1). The sequence of the peptides referred to by the first 3 amino acids is listed in “Patients, materials, and methods.”
ND indicates not done, as no informative peptides were available.
For patient 815, there were no informative peptides available.